Company news: IMS Health, Havas Drive, Healthline Networks

Share this article:
IMS Health launched the IMS Institite for Healthcare Informatics, a bigthink initiative focusing on the use of medical information globally, the future global role of biopharmas, the role of innovation in health system products, processes and delivery systems, and advancement of healthcare agendas in developing nations.

Family practitioners are consistently the physicians most targeted by industry emails, but specialty physicians are more likely to open and click, a survey by Cegedim's SK&A unit found. In 2010, around 17% of all emails targeted family practitioners, but the highest open rates were for trauma surgeons (13.4%), hepatologists (13.2%) and dermatopathologists (11.1%).

Healthline Networks added several publishing partners to its media network, including Ask.com, DoctorOz.com, DailyStrength, DailyRx, Inspire and the Forward Health group, (Women's Health Base, Men's Health Base, All-Allergines.com and Good Cholesterol Count.com). The San Francisco-based firm claims a potential reach of 43 million unique visitors each month.

Havas Drive launched a unit offering “patient-centric services geared toward persons with disabilities and those undergoing rehabilitative therapies.” The new unit will offer strategic and technological products – including tablets, gaming consoles, haptic interfaces, virtual prosthetics, adaptive therapies, text-to-speech functionality and Second Life – serving populations with low vision, blindness, autism, degermative illnesses, behavioral disorders, cognitive difficulty and the hearing impaired.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

India's Marck gets FDA Warning Letter

Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.